Invest in the Future of Noninvasive Point-of-Care Diagnostics

A fully de-risked science, patent-protected asset engineered for rapid commercialization and strategic acquisition.

The Commercial Opportunity

Replacing a $2,000 Hospital Protocol with a $30 Test

Gaia Medical Institute is replacing the legacy “wait-and-see” concussion protocol with an accessible, rapid test. By eliminating the need for expensive imaging and blood draws, BrainGuardian is positioned to capture the $7.5B U.S. youth sports market and critical dual-use military applications.

Parents already spend upwards of $900 per child per sport season on equipment and travel. A $30 test to know whether their child has a brain injury is an easy, out-of-pocket purchase — cheaper than a pair of cleats.

$7.5B
U.S. youth sports entry market
60M
Youth athletes in the U.S.
~80%
Target gross margins at scale
Why Partner with Gaia

Capital-Efficient Execution

🏭

Turnkey Manufacturing

We partnered with True Diagnostics (FDA-registered, GMP) and Qoolabs (ISO17025 GMP) to automate production — eliminating massive fixed capital expenditures. Domestic production, no off-shoring. We’re not building a factory. We’re turning one on.

📈

High-Margin Economics

Our lateral flow platform achieves unit manufacturing costs of $5–$7 at scale, yielding approximately 80% gross margins. Distribution through True Diagnostics’ existing retail channels: CVS, Walgreens, Walmart, Target.

🛠

Clear FDA Pathway

Actively executing FDA De Novo and Breakthrough Device Designation pathways, guided by NJK Associates — regulatory veterans who cleared the blood-based TBI biomarkers through the FDA. Budgeted conservatively for the more rigorous De Novo route.

De-Risked Asset Base

$15.8M Already Invested — By the U.S. Government

NIH, CDC, Department of Defense, and Chuck Noll Foundation funded the hard science. The technology risk is behind us.

$10M
Non-dilutive research cash (discounted from $15.8M for age)
$5M
Clinical saliva biobank (5,000+ samples)
$5M
9 issued patents + freedom to operate
$3M
Digital/AI saliva assay platform

Conservative replacement valuation: >$25M

Exit Strategy

Building for Scale, Designing for Early Exit

We are engineering this asset for a targeted M&A exit to a major diagnostics company by mid-2027. In the diagnostics space, acquirers buy de-risked assets to feed their global distribution channels — not revenue streams.

Comparable exits in point-of-care diagnostics:

  • SpinChip Diagnostics — Acquired by bioMérieux (2025) for $150M. Pre-revenue startup in clinical testing.
  • Banyan Biomarkers — Acquired by bioMérieux (2021). FDA-cleared blood biomarkers for TBI.
  • Astute Medical — Acquired by bioMérieux (2018) for $90M. FDA-cleared acute kidney injury test.
  • GeneWEAVE — Acquired by Roche (2015) for $425M. Early-stage startup.

Seed Milestones → Exit Triggers

  • Working commercial device (prototype LFA)
  • Clinical testing with youth athletes
  • Known FDA pathway (De Novo)
  • Breakthrough Device Designation filed
  • Patented recombinant antibody IP
  • Exclusive antibody supply chain secured

These milestones position the company for an early exit in 2027 via strategic acquisition by a major diagnostics company.

Risk Mitigation

Key Risks and Our Response

Risk Mitigation Potential Impact
Regulatory Retained NJK Associates (30+ years FDA experience, cleared blood TBI biomarkers). Pursuing FDA Q-Sub / Breakthrough Device pathway. Budgeted for the more rigorous De Novo route. Increased cost, delayed timeline
Manufacturing Partnered with True Diagnostics (FDA-registered U.S. facility) with automated, high-volume LFA capacity. Domestic production provides quality control, shorter lead times, and reliable supply chain. Inability to hit $5–$7 COGS target
Competitive 9 issued patents protect saliva-based TBI biomarker and cellular testing method. Competitors cannot match test sensitivity without infringing. Most recent patent issued July 2025. Loss of market share
Market Adoption Initial buy-in from institutional customers secured via KOLs at leading academic centers. Test is reimbursable (ICD-10-CM code Z13.850). Low retail price (<$30) removes insurance bottlenecks. Slower revenue ramp-up
Current Round

$2M Seed Round — Now Open

Post-Money SAFE, structured in two tranches.

Tranche 1 — Open Now

$500K

$12M cap — 20% discount off Tranche 2

Tranche 2 — After Tranche 1

$1.5M

$15M cap — Standard terms

We are opening early allocations for our commercial Seed round to fund the final physical prototype and FDA regulatory submissions.

Request the Investor Deck

We personally review all investor inquiries and will follow up within 24–48 hours.